Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Joch, S; Smolle, MA; Kashofer, K; Thüringer, A; Szkandera, J; Benesch, M; El-Heliebi, A; Liegl-Atzwanger, B; Leithner, A; Seidel, MG.
New Insights from Long-Term Clinical Use of Circulating Tumor DNA-Based Minimal Residual Disease Monitoring in Translocation-Associated Sarcomas.
Oncol Res Treat. 2025; 48(4):186-196
Doi: 10.1159/000543223
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kashofer Karl
- Smolle Maria Anna
- Co-Autor*innen der Med Uni Graz
- Benesch Martin
- El-Heliebi Amin
- Leithner Andreas
- Liegl-Atzwanger Bernadette
- Seidel Markus
- Szkandera Joanna
- Thüringer Andrea
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- INTRODUCTION: Assessment of circulating tumor DNA (ctDNA) as a means to monitor disease activity in translocation-associated tumors has become very popular in clinical practice. However, there are still few studies on its clinical application to date. Our study evaluates the clinical applicability of ctDNA as a biomarker for monitoring minimal residual disease (MRD) in patients with translocation-associated sarcomas. METHODS: In this retrospective study, we correlated 285 ctDNA samples from 34 patients diagnosed with translocation-associated sarcoma with the clinical course and images. Blood samples were collected at multiple time points during follow-up (median: 97 weeks, range: 7-398). RESULTS: We discovered a significant association between ctDNA levels and the clinical course of the disease, particularly noting differences between patients in remission or with progressive disease (p = 0.001). Furthermore, although we noted that ctDNA levels remained undetectable in a few cases of unilocular recurrence (n = 3), they were consistently higher in patients with multilocular recurrence (n = 14; p = 0.008). CONCLUSION: Monitoring ctDNA levels provides highly specific, additional information enabling early recurrence detection in patients with translocation-associated sarcomas during the follow-up and can be integrated into clinical practice. However, MRD monitoring by ctDNA quantification alone does not allow the reliable detection of 100% of unilocular recurrences and should be complemented by the use of conventional imaging techniques. INTRODUCTION: Assessment of circulating tumor DNA (ctDNA) as a means to monitor disease activity in translocation-associated tumors has become very popular in clinical practice. However, there are still few studies on its clinical application to date. Our study evaluates the clinical applicability of ctDNA as a biomarker for monitoring minimal residual disease (MRD) in patients with translocation-associated sarcomas. METHODS: In this retrospective study, we correlated 285 ctDNA samples from 34 patients diagnosed with translocation-associated sarcoma with the clinical course and images. Blood samples were collected at multiple time points during follow-up (median: 97 weeks, range: 7-398). RESULTS: We discovered a significant association between ctDNA levels and the clinical course of the disease, particularly noting differences between patients in remission or with progressive disease (p = 0.001). Furthermore, although we noted that ctDNA levels remained undetectable in a few cases of unilocular recurrence (n = 3), they were consistently higher in patients with multilocular recurrence (n = 14; p = 0.008). CONCLUSION: Monitoring ctDNA levels provides highly specific, additional information enabling early recurrence detection in patients with translocation-associated sarcomas during the follow-up and can be integrated into clinical practice. However, MRD monitoring by ctDNA quantification alone does not allow the reliable detection of 100% of unilocular recurrences and should be complemented by the use of conventional imaging techniques.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Neoplasm, Residual - genetics, blood, diagnosis
- Circulating Tumor DNA - blood, genetics
- Sarcoma - genetics, blood, pathology, diagnosis, therapy
- Male - administration & dosage
- Female - administration & dosage
- Adult - administration & dosage
- Retrospective Studies - administration & dosage
- Translocation, Genetic - administration & dosage
- Biomarkers, Tumor - blood, genetics
- Middle Aged - administration & dosage
- Neoplasm Recurrence, Local - genetics, blood
- Young Adult - administration & dosage
- Adolescent - administration & dosage
- Aged - administration & dosage
- Child - administration & dosage
- Follow-Up Studies - administration & dosage
- Find related publications in this database (Keywords)
- Liquid biopsy
- Translocation-associated sarcomas
- Cell-free circulating tumor DNA
- Minimal residual disease monitoring